Umdondoshiya wemithi uLilly, inkampani yaseMelika, kanye neNovo Nordisk, inkampani yaseDenmark, bamemezele ngokulandelana idatha yokuthengisa yemikhiqizo yabo eyinhloko ngo-2020: I-Dulaglutide isiphenduke umuthi we-TOP1 GLP-1, ngokuthengiswa kwama- $ 5.07Bn ngo-2020, unyaka- ukunyuka konyaka ngama-22.8%;i-liraglutide Ukuqala ukungena esikhathini sokwehla, ukuthengiswa ngo-2020 kwehle kusuka ku-$4.14Bn kuya ku-$3.93Bn, ukwehla konyaka nonyaka ngo-5.1%;I-semaglutide ikhule ngokushesha okukhulu, ukuthengiswa kufinyelela ku- $ 3.72Bn ngo-2020, okuwukukhuphuka konyaka ngo-119.9%.
I-Dulaglutide ka-Lilly (igama lokuhweba i-Trulicity®) yethulwa ngo-2014 futhi yaba isidakamizwa esinamandla esithengiswa ngo-$5.07Bn eminyakeni engu-6 nje kuphela, yaba umpetha wokuthengisa wezidakamizwa ze-GLP-1.Umkhiqizo owodwa weNovo Nordisk usalele ngemuva kukaLilly okwesikhashana.I-liraglutide yayo (igama lokuhweba i-Victoza® kanye ne-Saxenda®), eyethulwe ngo-2009, yake yaba ngumpetha wokuthengisa wezidakamizwa ze-GLP-1, futhi ukuthengiswa kwayo okuphezulu ngo-2017 kwafinyelela ku- $ 4.37Bn, yize kunezinkomba ezimbili zohlobo lwesifo sikashukela kanye nokukhuluphala. , idatha yango-2020 ibonisa ukuthi imakethe yalo muthi ingene enkathini yokwehla.Yona leyo semaglutide ye-Novo Nordisk (amagama okuhweba i-Ozempic® ne-Rybelsus®) ikhule ngokushesha futhi isikhule yaba esinye isidakamizwa esinamandla esithengiswa ngo-$3.72Bn eminyakeni emithathu.Isidakamizwa sinezinhlobo ezimbili zomthamo womjovo kanye namalungiselelo omlomo.
Ngokombono wendawo, i-United States iyizwe eliyinhloko lokuthengisa le-liraglutide, ibalwa cishe ngama-60% ngo-2020, ukwehla konyaka nonyaka ngo-11.02%;futhi wukwehla komnotho e-United States okudale ukwehla kwemakethe yomhlaba wonke ye-liraglutide.Isifunda se-EMEA (Europe, Middle East, Africa) sikhule kancane, ne-CAGR ye-1.6% kuphela eminyakeni emihlanu edlule;I-China iyimakethe ekhula ngokushesha kakhulu, ethengiswa ngama- $ 182.50Mn ngo-2020, enezinga lokukhula elihlanganisiwe lonyaka lama-42.39%.Njengoba i-semaglutide ibilokhu isemakethe maduze, zonke izimakethe zisezingeni lokukhula ngokushesha.I-United States iseyimakethe enkulu kunazo zonke, ibala u-80.04% wokuthengisa ngo-2020, ukwanda konyaka ngonyaka kwe-106.08%;I-EMEA inesabelo esingu-13.64% kuphela kodwa izinga lokukhula konyaka nonyaka lika-249.65%.I-Semaglutide yethulwa eChina ngo-2020 ngokuthengiswa kwe- $ 1.61Mn.Umfanekiso 3 ubonisa isimo sesifunda se-dulaglutide.Njengemakethe enkulu kunazo zonke, i-United States inokuthengiswa okufika ku-$3.836Bn, okubalelwa ku-75.69%, ngenani lokukhula elihlanganisiwe lonyaka lama-79.18%.
Amalungelo obunikazi ayisisekelo e-liraglutide (i-Victoza® ne-Saxenda®) aphelelwe yisikhathi e-China futhi asezophelelwa yisikhathi e-US, Japan nase-Germany.Impi kaTeva yelungelo lobunikazi no-Novo Nordisk isixazululiwe, futhi inguqulo ye-Teva ejwayelekile izotholakala ngo-2023. U-Mylan uphinde wafaka isicelo se-ANDA ku-FDA se-liraglutide ngesimangalo se-PIV.Ngokuphelelwa yisikhathi kancane kancane kwamalungelo obunikazi ayisisekelo kanye nokusatshiswa kwabakhiqizi bemithi ejwayelekile, umuthi uzongena kancane kancane enkathini yokuncipha.I-patent ehlanganisiwe yase-US ye-Trulicity® ngeke iphelelwe yisikhathi kuze kube ngu-2027, kuyilapho amalungelo obunikazi ayinhlanganisela yamazwe amakhulu ase-Europe kanye ne-Japan ngeke aphelelwe yisikhathi kuze kube ngu-2029, futhi ukuvikelwa kwelungelo lobunikazi okuyisisekelo kude kunokwe-liraglutide.Amalungelo obunikazi ayisisekelo e-semaglutide (Ozempic® ne-Rybelsus®) azophelelwa yisikhathi ngo-2032 maduze nje, futhi sisenendawo enkulu yokukhula kwemakethe, kodwa isikhathi sayo sokuphelelwa yisikhathi e-China ngu-2026.
Isikhathi sokuthumela: Jul-25-2022